STOCKS TELEGRAPH

Tag: MBOT STOCK

  • Pre-Market Rally Continues For Microbot Medical (MBOT) Stock

    Pre-Market Rally Continues For Microbot Medical (MBOT) Stock

    As trading begins, the stock price of Microbot Medical Inc. (NASDAQ: MBOT) is continuing to rise. MBOT shares have increased 15.29% to $2.94 as of the most recent pre-market check, building on the previous session’s 17.51% rise that ended at $2.55. This increasing trend comes after important late-breaking study evidence was recently accepted, which boosted investor confidence.

    Results of the Liberty Trial will be presented at the SIR Annual Meeting.

    A late-breaking abstract from Microbot Medical’s ACCESS-PVI study was accepted for presentation at the next Society of Interventional Radiology (SIR) annual conference, the company reported last week. The trial’s results will be presented on a podium during the conference, which is scheduled to take place in Nashville, Tennessee, from March 29 to April 2, 2025.

    The performance and safety of LIBERTY, a remote-controlled, single-use robotic device intended for peripheral vascular treatments, are being evaluated in the ACCESS-PVI trial, a prospective, multicenter, single-arm research. The study is called “Remote-controlled endovascular navigation using a small, disposable robotic device.” Results of the ACCESS-PVI trial,” will be presented by Dr. François Cornelis, MD, PhD, FCIRSE, of Memorial Sloan Kettering Cancer Center’s Department of Radiology.

    The acceptance of this late-breaking abstract marks a crucial milestone for Microbot Medical, as it provides an opportunity for Principal Investigators to showcase the LIBERTY system to a highly relevant audience—potential users within the interventional radiology community.

    Increasing Operations Prior to the Commercial Launch of LIBERTY

    Microbot Medical has named Ms. Michal Ahuvia Director of Operations in anticipation of LIBERTY’s expected commercial launch in the second quarter of 2025. Ms. Ahuvia will be in charge of increasing output and improving operational efficiency, reporting to Simon Sharon, the company’s general manager and chief technology officer.

    With more than 20 years of operations expertise in areas such as supply chain management, logistics, material planning, and process transformation, Ms. Ahuvia is anticipated to be essential in carrying out Microbot Medical’s business plan. Her experience will be crucial in streamlining production procedures as the business expands LIBERTY’s output in order to successfully satisfy consumer demand.

  • Microbot (MBOT) Captures Pre-Market Momentum With An Equity Move

    Microbot (MBOT) Captures Pre-Market Momentum With An Equity Move

    The news of a major equity move is causing Microbot Medical Inc. (NASDAQ: MBOT) to see an increase in stock price. MBOT shares were trading at $2.48 as of the most recent pre-market check, representing a strong 15.89% rise. The company’s definitive agreements for a registered direct offering and a simultaneous private placement are what caused the spike.

    Details of the Equity Offering

    Microbot Medical announced its intentions to sell 4,000,002 shares of its common stock at a price of $1.75 each through a registered direct offering. Furthermore, unregistered short-term series G preferred investment options will be offered by MBOT in a private placement.

    These options, which allow the purchase of up to 8,000,004 shares of Microbot Medical common stock at $1.75 per share, will be immediately exercisable and remain valid for two years. The transactions are expected to close imminently, with gross proceeds projected to reach approximately $7 million.

    Strategic Focus on LIBERTY Robotic System

    Proceeds from these offerings will primarily support the continued development, commercialization, and regulatory activities for the company’s flagship product, the LIBERTY Robotic System. The funds that will be raised will also go toward basic business needs and the expansion of products based on Microbot Medical’s portfolio of intellectual property. With its FDA 510(k) application, LIBERTY has achieved a crucial milestone, taking a big step closer to its planned commercial launch in Q2 2025.

    Setting Up for Growth in 2025

    By the end of 2024, Microrobot Medical had made significant strides toward its three main goals: finishing the FDA 510(k) application, building pre-commercial infrastructure, and carrying out strategic plans to guarantee a successful launch. By mid-2025, the business plans to start commercializing LIBERTY in the United States while obtaining further regulatory clearances in foreign regions. 

    These initiatives demonstrate Microbot Medical’s dedication to fostering innovation and attaining long-term success. Investor trust in MBOT’s strategic direction and ability to take advantage of new prospects in robotic medical technology is demonstrated by the market’s favorable reaction to the company’s stock developments.

  • Mircobot Medical Inc. (MBOT) Stock Fall Under Corrections After Hours

    Mircobot Medical Inc. (MBOT) stock skyrocketed after the company announced its strategic collaboration with Stryker Corporation on Monday. Under the collaboration, the companies will develop LIBERTY® Robotic System for neurovascular applications. The huge gains on the news were ultimately followed by a fall. Hence, the stock fell under corrections in the after-hours, shedding its gains.

    During the regular session, the stock gained 65.13% on the collaboration at $8.95 with over 90.9 million shares exchanging. This led to the fall of the stock in the after-hours, causing it to lose 9.94% at $8.06.

    More about MBOT

    Currently, the pre-clinical medical device company, Mircobot Medical Inc. has a market capitalization of $38.53 million. Furthermore, the company has 7.11 million shares outstanding in the market.

    On Monday, MBOT’s share price spiked up to a high of $9.60 on the news of the collaboration. The stock reached such a high after more than nine months at a hefty volume. The news of the collaboration had investors flocking towards the stock, as the volume reached 6,314% of its 65-day average of 1.44 million. Ultimately, MBOT was due to fall under corrections, as it happened in the after-hours on Monday.

    MBOT’s Collaboration with Stryker

    As per the collaboration with the medical technology company, Stryker, the companies will combine their technologies and expertise to develop the world’s first dedicated robotic procedural kit. Stryker’s Neurovascular instruments will be integrated into MBOT’s Liberty robotic system to develop the kit.

    Moreover, MBOT will also continue working independently on the Liberty system for peripheral and coronary procedures use. Furthermore, the animal feasibility studies of MBOT so far have supported the assertion that the technology can be potentially used to conduct the procedures. Hence, this will not only reduce the risk of radiation exposure and physical strain but also cut down on expensive capital equipment.

    Previous Developments Regarding the Liberty System

    As announced on December 23, the company previously secured a third patent for the robotic system in the U.S. Moreover, MBOT was able to secure all three patents in 2021. Furthermore, the company has a total of 47 patents now, with an additional 26 pending and more being submitted.

    As per December 15’s announcement, the company also met its previously stated milestone and achieved Design Freeze for the Liberty robotic system.

    In addition, MBOT also expects to file pre-submission with the FDA in the first quarter of 2022.